Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

No trades
See on Supercharts
Market capitalization
‪129.85 M‬USD
−0.2550USD
‪−32.54 M‬USD
‪146.79 M‬
Beta (1Y)
0.71

About Citius Pharmaceuticals, Inc.

CEO
Leonard L. Mazur
Headquarters
Cranford
Employees (FY)
22
Founded
2007
ISIN
US17322U2078
FIGI
BBG001QQH2N3
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CTXR is 0.8967 USD — it has increased by 9.86% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Citius Pharmaceuticals, Inc. stocks are traded under the ticker CTXR.
Citius Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
CTXR stock is 35.95% volatile and has beta coefficient of 0.71. Check out the list of the most volatile stocks — is Citius Pharmaceuticals, Inc. there?
One year price forecast for Citius Pharmaceuticals, Inc. has a max estimate of 4.0000 USD and a min estimate of 4.0000 USD.
CTXR earnings for the last quarter are −0.07 USD whereas the estimation was −0.02 USD which accounts for −250.00% surprise. Estimated earnings for the next quarter are 0.13 USD. See more details about Citius Pharmaceuticals, Inc. earnings.
Citius Pharmaceuticals, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪21.30 M‬ USD.
Yes, you can track Citius Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
CTXR stock has risen by 3.07% compared to the previous week, the month change is a 21.18% rise, over the last year Citius Pharmaceuticals, Inc. has showed a 45.65% decrease.
CTXR net income for the last quarter is ‪−9.23 M‬ USD, while the quarter before that showed ‪−9.94 M‬ USD of net income which accounts for 7.17% change. Track more Citius Pharmaceuticals, Inc. financial stats to get the full picture.
Today Citius Pharmaceuticals, Inc. has the market capitalization of ‪129.85 M‬, it has decreased by 1.60% over the last week.
No, CTXR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTXR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Citius Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
CTXR reached its all-time high on Feb 9, 2016 with the price of 37.4813 USD, and its all-time low was 0.4000 USD and was reached on Dec 5, 2019.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 22.00 employees. See our rating of the largest employees — is Citius Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Citius Pharmaceuticals, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Citius Pharmaceuticals, Inc. stock shows the sell signal. See more of Citius Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Citius Pharmaceuticals, Inc. future price: according to them, CTXR price has a max estimate of 4.00 USD and a min estimate of 4.00 USD. Read a more detailed Citius Pharmaceuticals, Inc. forecast: see what analysts think of Citius Pharmaceuticals, Inc. and suggest that you do with its stocks.